Two key obstacles to efficient experimental therapeutics for cognitive impairment (CI) associated with Parkinson's disease (PD) are lack of accurate prediction of which patients are at highest risk for CI in the near term, and heterogeneity in the pathology underlying CI in PD and Parkinson's disease dementia (PDD). Project 1 will address both of these critical issues. The first goal of the project is to improve the ability to predict which patients with PD are at highest risk for developing CI by building a predictive model that combines clinical and biomarker data. The second goal of the project is to better understand potential pathological subtypes of dementia in PDD and Lewy Body Dementia (LBD) by examining patterns of expression of clinical and biomarker features which may reflect different underlying pathology.
The specific aims of Project 1 are: 1) to replicate previously-reported candidate biomarkers of CI in a training cohort of LBSD patients;2) to define relationships among candidate biomarkers in Aim 1 to identify potential pathophysiological subtypes of cognitive impairment in PD and DLB;and 3) to develop a multimodal predictive algorithm for cognitive decline in PD and apply it to an independent test cohort of PD patients. We will accomplish these aims in the context of longitudinal cohort study that uses data already collected in the first funding cycle of the Penn Udall Center along with additional data collected in this cycle. We will use Hierarchical Cluster Analysis and Principal Components Analysis to examine patterns of clinical and biomarker expression. We will use a split-sample approach to developing and testing the predictive algorithm. The products of this study will be a deeper understanding of the inter-relations of clinical and biological features of CI in PD and a practical tool for assessing the risk of developing this disabling complication.

Public Health Relevance

Parkinson's disease (PD) is a common neurodegenerative disease affecting approximately 1 million Americans. While the motor symptoms of PD are well-recognized and can be targeted by effective symptomatic medications, cognitive impairment and dementia in PD are common (affecting 80% of patients with PD for 20 years), costly, and without effective symptomatic therapies. This project seeks to develop clinically useful biomarkers for predicting and monitoring the development of cognitive impairment in PD, thus removing significant roadblocks to the development of effective therapies for this important, currently untreatable, aspect of disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS053488-06
Application #
8435739
Study Section
Special Emphasis Panel (ZNS1-SRB-J (01))
Project Start
2007-06-15
Project End
2017-06-30
Budget Start
2012-09-01
Budget End
2013-06-30
Support Year
6
Fiscal Year
2012
Total Cost
$277,203
Indirect Cost
$103,951
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tropea, Thomas F; Xie, Sharon X; Rick, Jacqueline et al. (2017) APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. Mov Disord :
Schrag, Anette; Siddiqui, Uzma Faisal; Anastasiou, Zacharias et al. (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol 16:66-75
Cousins, Katheryn A Q; Ash, Sharon; Grossman, Murray (2017) Production of verbs related to body movement in amyotrophic lateral sclerosis (ALS) and Parkinson's Disease (PD). Cortex :
Rennert, Lior; Xie, Sharon X (2017) Cox regression model with doubly truncated data. Biometrics :
St John-Williams, Lisa; Blach, Colette; Toledo, Jon B et al. (2017) Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Sci Data 4:170140
Ash, Sharon; Jester, Charles; York, Collin et al. (2017) Longitudinal decline in speech production in Parkinson's disease spectrum disorders. Brain Lang 171:42-51
Lopez, Alexander M; Weintraub, Daniel; Claassen, Daniel O (2017) Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy. Semin Neurol 37:186-192
Akhtar, Rizwan S; Xie, Sharon X; Chen, Yin J et al. (2017) Regional brain amyloid-? accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS One 12:e0177924
Cooper, Christine A; Jain, Nimansha; Gallagher, Michael D et al. (2017) Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Ann Clin Transl Neurol 4:15-25
Rutten, Sonja; Vriend, Chris; van der Werf, Ysbrand D et al. (2017) The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. Parkinsonism Relat Disord 39:31-36

Showing the most recent 10 out of 301 publications